Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models

Chen,Yan; Li,Zhengyang; Yang,Yan; Lin,Lin; Zhang,Hongjie

doi:10.3892/ijmm.2013.1252

Role of glucagon-like peptide-1 in the pathogenesis of experimental irritable bowel syndrome rat models

Authors:
- Yan Chen
- Zhengyang Li
- Yan Yang
- Lin Lin
- Hongjie Zhang
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: January 22, 2013 https://doi.org/10.3892/ijmm.2013.1252
Pages: 607-613

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in gut motility and visceral hypersensitivity are two major features of irritable bowel syndrome (IBS). The aim of this study was to investigate the roles of glucagon-like peptide-1 (GLP-1) in the pathogenesis of experimental IBS. Rat models of constipation-predominant IBS (IBS-C) and diarrhea-predominant IBS (IBS-D) were established. Fecal water content and behavioral responses to colorectal distention (CRD), using electromyography (EMG), were measured. The expression of glucagon-like peptide-1 receptor (GLP-1R) in the colon was detected by immunohistochemistry, and the serum concentration of GLP-1 was measured by ELISA assay. The movement of circular and longitudinal colonic muscle was detected using an organ bath recording technique. Compared to controls, the fecal water contents were lower in the IBS-C group, while they were higher in the IBS-D group (P<0.05). EMG response to CRD in the experimental IBS groups was increased compared with their respective controls (P<0.05). GLP-1R was localized in the mucosa layer, circular muscle and myenteric nerve plexus of the colon. Notably, the expression of GLP-1R in the IBS-C group was higher, but in the IBS-D group, it was lower compared with controls. The serum levels of GLP-1 in the IBS-C group were higher compared to those in the IBS-D group (P<0.05). In addition, administration of exogenous GLP-1 and exendin-4 inhibited colonic circular muscle contraction, particularly in the IBS-C group, while there was no significant effect on longitudinal muscle contraction. In conclusion, these results indicated that GLP-1 and GLP-1R are implicated in the pathogenesis of IBS-C and IBS-D.

View Figures

View References

1	Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 130:1377–1390. 2006. View Article : Google Scholar : PubMed/NCBI
2	Clarke G, Quigley EM, Cryan JF and Dinan TG: Irritable bowel syndrome: towards biomarker identification. Trends Mol Med. 15:478–489. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cremonini F and Talley NJ: Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 34:189–204. 2005. View Article : Google Scholar : PubMed/NCBI
4	Spiller RC and Thompson WG: Bowel disorders. Am J Gastroenterol. 105:775–785. 2010. View Article : Google Scholar : PubMed/NCBI
5	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
6	Camilleri M, McKinzie S, Busciglio I, et al: Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 6:772–781. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hellstrom PM, Hein J, Bytzer P, Bjornsson E, Kristensen J and Schamby H: Clinical trial: the glucagon-like peptide-1 receptor agonist ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study. Aliment Pharmacol Ther. 29:198–206. 2009. View Article : Google Scholar : PubMed/NCBI
8	Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J and Marks V: Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 138:159–166. 1993.
9	Hellstrom PM, Naslund E, Edholm T, et al: GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 20:649–659. 2008. View Article : Google Scholar : PubMed/NCBI
10	McDonagh SC, Lee J, Izzo A and Brubaker PL: Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine. Am J Physiol Gastrointest Liver Physiol. 293:G461–G468. 2007. View Article : Google Scholar : PubMed/NCBI
11	Miki T, Minami K, Shinozaki H, et al: Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes. 54:1056–1063. 2005. View Article : Google Scholar : PubMed/NCBI
12	Schirra J, Houck P, Wank U, Arnold R, Goke B and Katschinski M: Effects of glucagon-like peptide-1(7–36)amide on antro-pyloroduodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut. 46:622–631. 2000.
13	Schirra J, Nicolaus M, Roggel R, et al: Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antropyloro-duodenal motility in humans. Gut. 55:243–251. 2006. View Article : Google Scholar : PubMed/NCBI
14	Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG and Mulè F: Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 22:e664–e203. 2010. View Article : Google Scholar : PubMed/NCBI
15	Körner M, Stöckli M, Waser B and Reubi JC: GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 48:736–743. 2007.PubMed/NCBI
16	Peng LH, Yang YS, Sun G and Wang WF: A new model of Constipation-predominant irritable bowel syndrome in rats. Shijie Huaren Xiaohua Zazhi. 12:112–116. 2004.(In Chinese).
17	Williams CL, Villar RG, Peterson JM and Burks TF: Stress-induced changes in intestinal transit in the rat: a model for irritable bowel syndrome. Gastroenterology. 94:611–621. 1988.PubMed/NCBI
18	Gui XY, Pan GZ and Ke MY: Residual effect of cold-restraint stress on colonic motility in rats. Chin J Dig Dis. 17:94–96. 1997.(In Chinese).
19	Habold C, Reichardt F, Le Maho Y, et al: Clay ingestion enhances intestinal triacylglycerol hydrolysis and non-esterified fatty acid absorption. Br J Nutr. 102:249–257. 2009. View Article : Google Scholar : PubMed/NCBI
20	Winston J, Shenoy M, Medley D, Naniwadekar A and Pasricha PJ: The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology. 132:615–627. 2007. View Article : Google Scholar : PubMed/NCBI
21	Al-Chaer ED, Kawasaki M and Pasricha PJ: A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology. 119:1276–1285. 2000. View Article : Google Scholar : PubMed/NCBI
22	Appleyard CB and Wallace JL: Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol. 269:G119–G125. 1995.PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[−Delta Delta C(T)] method. Methods. 25:402–408. 2001.
24	Tolessa T, Gutniak M, Holst JJ, Efendic S and Hellstrom PM: Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci. 43:2284–2290. 1998. View Article : Google Scholar : PubMed/NCBI
25	Näslund E, Bogefors J, Skogar S, et al: GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol. 277:R910–R916. 1999.PubMed/NCBI
26	Nagell CF, Wettergren A, Ørskov C and Holst JJ: Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol. 41:667–672. 2006. View Article : Google Scholar : PubMed/NCBI
27	Bozkurt A, Näslund E, Holst JJ and Hellström PM: GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regul Pept. 107:129–135. 2002. View Article : Google Scholar : PubMed/NCBI
28	Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M and Greenberg GR: Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J Clin Endocrinol Metab. 87:3078–3083. 2002. View Article : Google Scholar : PubMed/NCBI